http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1546134-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 |
| filingDate | 2003-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63531f2c220c07d517b7b028209bdea8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7083fe6d42ef1afa68959c51a8b608f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f201f57717123d5598b83ab6b8f60148 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da50d80664294a736d4e50af8b5cbb85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5adb1c87169b6da0a21dc4aefd3107c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cbc3c37256375a88934da7caa3872fc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed6afca0ec14ad286a7e24cbb2411207 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3606dac4947f7eb66ec2c3f136011ff5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58f9e9c98b4ad84ddb36822f817eade0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30f95edf6adbd938331abca6e148b63a |
| publicationDate | 2005-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1546134-A1 |
| titleOfInvention | Piperazine substituted aryl benzodiazepines |
| abstract | Described herein are compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, S, and O; Alk is (C<SUB>1-4</SUB>) alkylene or hydroxy substituted (C<SUB>1-4</SUB>) alkylene; X is oxygen or sulfur; R<SUP>1 </SUP>is hydrogen, (C<SUB>1-6</SUB>) fluroalkyl, (C<SUB>3-6</SUB>) cycloalkyl, or (C<SUB>1-4</SUB>) alkyl, wherein the (C<SUB>1-4</SUB>) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCH<SUB>2</SUB>CH<SUB>2</SUB>OH, or -CN; R<SUP>2 </SUP>is H, halogen, (C<SUB>1-6</SUB>) fluoroalkyl, (C<SUB>1-6</SUB>) cycloalkyl, OR<SUP>4</SUP>, SR<SUP>4</SUP>, NO<SUB>2</SUB>, CN, COR<SUP>4</SUP>, C(O)OR<SUP>4</SUP>, CONR<SUP>5</SUP>R<SUP>6</SUP>, NR<SUP>5</SUP>R<SUP>6</SUP>, SO<SUB>2</SUB>NR<SUP>5</SUP>R<SUP>6</SUP>, NR<SUP>5</SUP>COR<SUP>4</SUP>, NR<SUP>5</SUP>SO<SUB>2</SUB>R<SUP>4</SUP>, optionally substituted aromatic, or (C<SUB>1-6</SUB>) alkyl, wherein (C<SUB>1-6</SUB>) alkyl is unsubstituted or substituted with a hydroxy group; R<SUP>3 </SUP>is hydrogen (C<SUB>1-6</SUB>) fluoroalkyl, (C<SUB>2-6</SUB>) alkenyl, Ar, (C<SUB>1-4</SUB>)alkyl-Ar, or (C<SUB>1-4</SUB>) alkyl wherein (C<SUB>1-4</SUB>) alkyly is unsubstituted or substituted with a phenyl; R<SUP>4 </SUP>is hydrogen, (C<SUB>1-6</SUB>) alkyl, (C<SUB>1-6</SUB>) fluoroalkyl, or optionally substituted aromatic; R<SUP>5 </SUP>and R<SUP>6 </SUP>are independently hydrogen, (C<SUB>1-6</SUB>) alkyl, or optionally substituted aromatic, R<SUP>7 </SUP>is hydrogen, (C<SUB>1-6</SUB>) alkyl, (C<SUB>1-6</SUB>) fluoroalkyl, or optionally substituted aromatic; R<SUP>8 </SUP>and R<SUP>9 </SUP>are independently hydrogen, (C<SUB>1-6</SUB>) alkyl, or optionally substituted aromatic; Ar is optionally substituted phenyl, napthyl, monocyclic heteroaromatic or bicyclic heteroaromatic; Z<SUP>1 </SUP>and Z<SUP>2 </SUP>are independently selected from hydrogen, halogen, (C<SUB>1-6</SUB>) alkyl, (C<SUB>1-6</SUB>) fluoroalkyl, OR<SUP>7</SUP>, SR<SUP>7</SUP>, NO<SUP>2</SUP>, CN, COR<SUP>7</SUP>, CONR<SUP>8</SUP>R<SUP>9</SUP>, NR<SUP>8</SUP>R<SUP>9</SUP>, and optionally substituted aromatic; and all salts, solvates, optical and geometric isomers, and crystalline forms thereof. Also, described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treatment of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I) |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10624875-B2 |
| priorityDate | 2002-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2085.